Skip to main content
TISSUE REPAIR LTD logo

TISSUE REPAIR LTD — Investor Relations & Filings

Ticker · TRP ISIN · AU0000180887 ASX Professional, scientific and technical activities
Open in API
Filings indexed 139 across all filing types
Latest filing 2022-11-22 Investor Presentation
Country AU Australia
Listing ASX TRP

About TISSUE REPAIR LTD

https://tissuerepair.com.au/

Tissue Repair Ltd is a clinical-stage biopharmaceutical company focused on the development of advanced wound healing and skin repair agents. The company’s core technology centers on Glucoprime, a proprietary yeast-derived beta-glucan designed to stimulate the innate immune system and accelerate the body's natural healing processes. Its lead candidate, TR-987, is being developed for the treatment of chronic wounds, such as venous leg ulcers, and for use in post-procedural recovery following aesthetic treatments. By targeting the inflammatory phase of wound healing, the technology aims to improve clinical outcomes and reduce recovery times. The company focuses on addressing unmet needs in both the medical wound care and cosmetic dermatology markets through its specialized biological platform.

Recent filings

Filing Released Lang Actions
AGM Presentation 15 pages 1.2MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation dated 7 November 2022 by Tissue Repair Ltd, describing their technology platform, clinical trial phases, market opportunity, and product strategy. It includes forward-looking statements, disclaimers, and extensive information about the company's products and clinical development plans. The content is structured as an investor or corporate presentation focusing on technology, clinical progress, market potential, and strategic outlook. There are no financial statements, audit opinions, voting results, or regulatory certifications. The document is not a regulatory filing, earnings release, or annual/interim report. It is clearly a presentation intended for investors or stakeholders to inform about the company's business and strategy. Therefore, the most appropriate classification is Investor Presentation (IP).
2022-11-22 English
Results of Meeting 2 pages 156.1KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an ASX announcement dated 23 November 2022 reporting the results of an Annual General Meeting (AGM) for Tissue Repair Limited. It includes detailed proxy vote counts and poll results for resolutions passed at the AGM. The content focuses on shareholder voting outcomes rather than the meeting materials or presentations themselves. The document length is 3384 characters, which is relatively short and consistent with a voting results announcement rather than a full AGM presentation or annual report. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-11-22 English
Company Presentation 13 pages 1.2MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation dated 7 November 2022 by Tissue Repair Ltd. It contains extensive information about the company's technology platform, clinical trial phases, market opportunity, and product development strategy. The text explicitly states it is a "Presentation" and includes disclaimers that it is not a prospectus or offer of securities. The content focuses on business strategy, technology, clinical trial results, and market potential, typical of an investor presentation. There are no financial statements or audit information, nor is it a regulatory filing or earnings release. The length (15,000 characters) and detailed content support classification as an Investor Presentation rather than a brief summary or announcement. Therefore, the document best fits the category of Investor Presentation (IP).
2022-11-07 English
Bell Potter Healthcare Conference Invitation 1 page
Investor Presentation Classification · 95% confidence The document is an ASX announcement about Tissue Repair's participation in the Bell Potter Healthcare Conference, including details about the presentation date, time, and content focus. It is a brief announcement inviting investors or interested parties to attend the virtual conference presentation. There is no financial data, no detailed report, no voting results, no management changes, no legal proceedings, or other regulatory filings. The document is short (1536 characters) and serves as an event announcement rather than a report or transcript. Therefore, it fits best under Investor Presentation (IP) as it relates to a presentation for investors focusing on company updates and strategy.
2022-11-06 English
Quarterly Activities/Appendix 4C Cash Flow Report 11 pages 357.2KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 28 October 2022 titled 'September 2022 - Quarterly Activities Report & Appendix 4C'. It provides detailed updates on the company's progress during the September 2022 quarter, including operational highlights, manufacturing updates, regulatory interactions with the FDA, financial summaries including cash position and cash flow, and future activities. The document contains substantive financial data such as cash operating outflows, cash position, and use of funds compared to prospectus estimates. It also includes detailed business and clinical development updates. The presence of actual financial data and comprehensive quarterly operational information indicates this is a quarterly report rather than a brief announcement or a simple regulatory filing. The document is about 15,000 characters long, which is consistent with a full quarterly report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2022-10-27 English
Notice of Annual General Meeting/Proxy Form 18 pages 1.2MB
AGM Information Classification · 100% confidence The document is an ASX announcement dated 21 October 2022 regarding the Notice of Annual General Meeting (AGM) and related documents for Tissue Repair Limited. It includes the Notice of Meeting, Proxy Form, and Explanatory Statement for the AGM scheduled on 23 November 2022. The content focuses on the logistics of the AGM, voting instructions, agenda items including the Remuneration Report, election of directors, and an amendment to the constitution. There is no financial data or detailed financial performance analysis present; rather, it is a formal notice and explanatory materials for the AGM. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting. The document is lengthy (15,000 characters) and contains the full notice and explanatory statement, not just an announcement of the report or a brief summary. Therefore, the correct classification is AGM Information (AGM-R).
2022-10-20 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.